anxiety disorders, panic disorder, obsessive-compulsive disorder, phobias, post-traumatic stress disorder
| «« |
August 2006
|
»» | ||||
| S | M |
T
|
W | T | F | S |
| 1 |
2
|
3
|
4
|
5
|
||
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
| 13 |
14
|
15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | 31 | ||
- Trauma healing therapies
- No more Freud. No more Prozac.
- Serotonin Syndrome - what is it?
- Full LinkBlog
| Name |
(Note: anti spam delay set)
Anxiety Disorders Association
of America
Anxiety Network Australia
Anxiety-Panic.Com
BrainPhysics - OCD
Canadian Network for Mood
and Anxiety Treatments
Cognitive Behavior Therapy
David Baldwin's
Trauma Information Pages
EMDR Institute, Inc.
EMDR Network Japan
Living with a Brain Disorder
Morita Therapy
Mayo Clinic : Depression
Mayo Clinic : GAD
Mayo Clinic : OCD
Mayo Clinic : Panic Attacks
Mayo Clinic : PTSD
Mayo Clinic : Social Anxiety
Medicines.org.uk - Anxiety & Depression guides
Nation Center for PTSD
National Institute of Mental
Health (NIMH)
No Such Thing As Crazy
OCD Ireland
Obsessive Compulsive
Foundation
Open Minds, Open Doors
Partners With PTSD
Rational Emotive Behavior
Therapy
Sane Australia
Shyness & Social Anxiety Service of Australia
Social Anxiety - UK
Social Phobia/Social Anxiety Association
tAPir - the Anxiety Panic internet resource
The Panic Center
(Free CBT based programs)
Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.
Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.
Always consult your doctor if you are in any way concerned about your health.
Yul Brynner
Last Reset: 04:05, 14 May 06
CNS Drugs. 2006;20(6):465-76.
Long-term pharmacotherapy for post-traumatic stress disorder.
Davis LL, Frazier EC, Williford RB, Newell JM.
VA Medical Center, Tuscaloosa, Alabama, USAUniversity of Alabama School of Medicine, Birmingham, Alabama, USA.
This article reviews the literature on the long-term pharmacological treatment of post-traumatic stress disorder (PTSD).
A PUBMED search was conducted; only studies on the effects of long-term (>14-weeks) pharmacological treatment for PTSD in adults or children were considered.
Our search identified three randomised, double-blind, placebo-controlled studies (one each for sertraline, fluoxetine and risperidone), four open-label studies (one each for sertraline, paroxetine, nefazodone and valproate), one retrospective case series (clozapine) and one pooled analysis (sertraline). All studies involved adult populations, with the exception of the study of clozapine.
The studies demonstrate that long-term treatment of PTSD with SSRIs effectively maintains the previous treatment response and improvement in quality of life, converts more patients to responder status and accounts for one-third of overall treatment gains. Greater PTSD severity predicts a longer time to response to these drugs. Discontinuation of SSRI treatment after 12 weeks results in a greater risk of relapse and symptom exacerbation compared with extended treatment. In addition to improved PTSD symptoms, extended treatment with paroxetine improves verbal declarative memory and increases hippocampal volume.
Long-term treatment of PTSD with atypical antipsychotics (risperidone and clozapine), non-SSRI antidepressants (nefazodone) and antiepileptic drugs (AEDs; valproate) also appears to result in significant improvements in PTSD symptoms.
In conclusion, long-term treatment of PTSD with SSRIs improves the psychiatric and clinical outcome of patients with the disorder and prevents relapse and symptom exacerbation. The effect of other agents (atypical antipsychotics, AEDs and other psychotropic medications) requires further controlled study.
PMID: 16734498 [PubMed - in process]
(Text has been reformatted for clarity; Ed.)